Your search for major depressive disorder returned 206 results

Cognitive impairment in individuals with major depressive disorder should be treated as a primary problem.

Investigators sought to determine the frequency of major depressive disorder in patients in epilepsy clinics.

The FDA has cleared Nexstim’s NBT system for the treatment of major depressive disorder.

Mirtazapine is a central alpha-2 antagonist currently FDA-approved for the treatment of major depressive disorder.

Screening recommended for those aged 12 to 18, however there is insufficient evidence to assess for children aged 11 and younger.

For patients with major depressive disorde, relapse is associated with brain cortical changes over two years.

Migraine was more significantly associated with pain or muscle soreness than anxiety disorders in patients with depression.

Patients with type 2 diabetes and major depressive disorder spent a significant amount of time experiencing depressive episodes.

The influence of gut microbiota extends to the brain via neuroinflammation, resulting in symptoms associated with major depressive disorder.

Dr Amit Akirov examines the evidence suggesting associations between migraine and major depressive disorder (MDD).

Researchers conducted an 8-week, open-label, single-arm study and a subsequent 2-stage, sequential, parallel comparison study to assess the use of pimavanserin among patients with Parkinson disease and major depressive disorder.

Researchers found evidence for a divergent association between lifetime MDD and the prevalence and severity of symptoms in patients with migraine.

Migraine with active headache may predict other painful physical symptoms in patients with major depressive disorder.

HIV-infected adults with major depressive disorder have a 30% increased risk for acute myocardial infarction.

Researchers suggest that improvement in cognitive function should be a goal for major depressive disorder because their data showed little improvement in the cognitive abilities of patients with major depression after treatment with psychological interventions.

The goals of this study were to identify functional connectome fingerprints that predict symptom improvement with any treatment and with specific treatment.

A team of researchers sought to investigate the bidirectional relationship between multiple sclerosis and major depressive disorder with Mendelian randomization.

Researchers conducted a study to evaluate the validity of, and satisfaction with, the Cognition KIT DSST mobile app in patients with major depressive disorder.

Serotonergic antidepressants are effective for sleep disturbances in perimenopausal and postmenopausal women even without major depressive disorder.

More than half of individuals with prior COVID-19 illness have met the criteria for symptoms of major depressive disorder.

Testing for genetic variants may allow clinicians to predict how patients with major depressive disorder metabolize antidepressants.

While the relationship between current mood state and cognitive impairment is unclear, more severe depression has been linked to greater impairment.

Multimarker inflammatory biosignatures are expected to facilitate diagnosis and predict treatment outcomes for various central nervous system disorders, particularly Alzheimer disease and major depressive disorder.

The degree of overlap between MDD and burnout is unclear. However, dysfunctional sleep patterns are known risk factors for both conditions.

The researchers analyzed data from a large randomized noninferiority trial that compared theta-burst stimulation and high-frequency (10 Hz) rTMS delivered to the left dorsolateral prefrontal cortex.

Patients received 40 Hz gamma tACS to provide data on the use of varying stimulation periods.

Investigating whether serial ketamine treatments change functional connectivity between limbic structures and resting-state networks.

There was insufficient evidence to recommend screening in children aged 11 and younger.

The treatment is currently being evaluated in a Phase 2 study (ELEVATE) in patients with major depressive disorder who have had an inadequate response to standard antidepressant therapy.

The Food and Drug Administration (FDA) has granted Fast Track designation to an investigational intranasal formulation of racemic ketamine for the potential treatment of acute suicidal ideation and behavior in patients with major depressive disorder.